2024-10-16 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products, including treatments for diabetes, cancer, autoimmune diseases, and other conditions.

**Performance Highlights:**

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** LLY (899.89) significantly outperformed VOO (135.82).
* **Divergence:** The current divergence stands at 764.07, indicating LLY's substantial outperformance relative to VOO. This represents a high position (94.74%) within the historical divergence range. 

**2. Recent Price Movement:**

* **Closing Price:** $932.06
* **5-Day Moving Average:** $914.5
* **20-Day Moving Average:** $906.22
* **60-Day Moving Average:** $894.98

The stock price is currently trading above all three moving averages, suggesting a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 54.89, indicating neither overbought nor oversold conditions. 
* **PPO:** 0.31, suggesting a slight positive momentum.
* **Delta_Previous_Relative_Divergence:** -0.2, indicating a recent short-term downtrend in the stock's relative performance.
* **Expected Return:** 24.91%, representing the potential 5-year expected return over VOO.

**4. Recent Earnings and Forecast:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | $11.30 B |
| 2024-04-30 | 2.49 | $8.77 B |
| 2023-11-02 | -0.06 | $9.50 B |
| 2023-08-08 | 1.96 | $8.31 B |
| 2024-08-08 | 1.96 | $8.31 B |

The most recent earnings report for the quarter ending August 8, 2024, showed an EPS of $3.29, exceeding analyst expectations. The company also reported strong revenue growth, exceeding $11 billion. This positive earnings performance indicates strong underlying business fundamentals.

**5. News and Recent Issues:**

* **Recent Market Outlook:**  Analysts remain bullish on LLY's future prospects, citing continued strong demand for its products, particularly in the diabetes and oncology markets.
* **Analyst Opinions and Performance Highlights:** FINBOLD reported that several analysts upgraded their ratings on LLY recently, citing the company's strong earnings performance and positive growth prospects. 

**6. Overall Analysis:**

Eli Lilly and Co is a strong performer with a track record of outperforming the market. The company continues to demonstrate positive earnings performance and a robust product pipeline. While the stock has recently experienced some short-term weakness, the long-term outlook remains positive. The high expected return and strong technical indicators suggest potential further upside. Investors looking for exposure to the pharmaceutical sector might consider adding LLY to their portfolios.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Consult with a qualified financial advisor before making any investment decisions.
